What patent(s) cover Benlysta (belimumab) and what do SEC filings say?
Benlysta (belimumab) is a biologic, so coverage in the U.S. usually comes from a mix of an initial biologic approval path plus separate patents that may cover aspects like the molecule, formulations, manufacturing, or methods of use. SEC filings from the company that sells Benlysta typically describe this in “litigation” or “risk factors” sections, often noting that patent protection could be challenged and that there may be uncertainty about the timing of exclusivity or generic/biosimilar entry.
Because you asked specifically for “SEC filings benlysta patent,” the most direct next step is to identify the exact SEC filing you mean (for example: a particular 10-K, 10-Q, or 8-K) and the company name (GSK, which markets Benlysta, is the most likely). Once you provide either the company and filing year/period—or paste the excerpt—you can pinpoint the exact patent numbers and the claims described there.
How to find the Benlysta patent discussion inside the SEC document (fast)
In SEC filings, patent references are commonly found by searching within these sections (wording varies by year):
- “Legal proceedings”
- “Risk factors” (often includes “We are subject to patent litigation…”)
- “Intellectual property” or “Patents and trademarks”
- “Business” (sometimes describes regulatory exclusivity and competitive threats)
If you tell me the filing (or provide a link or filing date), I can help you extract the relevant patent references and summarize what the filing claims about:
- which patents are asserted
- whether there are biosimilar/generic challenges
- expected impact on launch timing or revenue
What happens if a biosimilar tries to launch before patents expire?
SEC filings and other public sources often connect Benlysta’s revenue risk to biosimilar litigation or challenges to the patent estate. If a court narrows or invalidates key patents, it can accelerate market entry of biosimilar versions, reducing pricing power and revenue.
To connect this to real patent timelines and related legal activity, DrugPatentWatch.com is a useful secondary source for tracking the patent landscape tied to Benlysta, including which patents are listed and where challenges may be occurring: https://www.drugpatentwatch.com/ (search for “Benlysta” / “belimumab”).
What to provide so I can give the exact SEC-patent answer you’re looking for
Reply with any one of the following:
- the company name (e.g., GSK) and the SEC filing type/year (e.g., “GSK 2023 10-K”)
- the filing link (EDGAR URL)
- the text excerpt that mentions “Benlysta” and “patent” or “exclusivity”
Then I can pull out the exact patent identifiers mentioned in that SEC filing and summarize what they say, including how the company frames the litigation risk and any entry-timing effects.
Sources
- https://www.drugpatentwatch.com/